RT Journal Article
SR Electronic
T1 Aging-induced isoDGR-modified fibronectin activates monocytic and endothelial cells to promote atherosclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.02.21252419
DO 10.1101/2021.03.02.21252419
A1 Park, Jung Eun
A1 JebaMercy, Gnanasekaran
A1 Pazhanchamy, Kalailingam
A1 Guo, Xue
A1 Ngan, SoFong Cam
A1 Kang Liou, Ken Cheng
A1 Lynn, Soe EinSi
A1 Ng, Ser Sue
A1 Meng, Wei
A1 Lim, Su Chi
A1 Leow, Melvin Khee-Shing
A1 Richards, A Mark
A1 Pennington, Daniel J
A1 de Kleijn, Dominique P.V.
A1 Sorokin, Vitaly
A1 Ho, Hee Hwa
A1 McCarthy, Neil E.
A1 Sze, Siu Kwan
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.03.02.21252419.abstract
AB Background and Aims Aging is the primary risk factor for cardiovascular disease (CVD), but the mechanisms underlying age-linked atherosclerosis remain unclear. We previously observed that long-lived vascular matrix proteins can acquire ‘gain-of-function’ isoDGR motifs that might play a role in atherosclerotic pathology.Methods IsoDGR-specific mAb were generated and used for ELISA-based measurement of motif levels in plasma samples from patients with coronary artery diseases (CAD) and non-CAD controls. Functional consequences of isoDGR accumulation in age-damaged fibronectin were determined by bioassay for capacity to activate monocytes, macrophages, and endothelial cells (signalling activity, pro-inflammatory cytokine expression, and recruitment/adhesion potential). Mice deficient in the isoDGR repair enzyme PCMT1 were used to assess motif distribution and macrophage localisation in vivo.Results IsoDGR-modified fibronectin and fibrinogen levels in patient plasma were significantly enhanced in CAD and further associated with smoking status. Functional assays demonstrated that isoDGR-modified fibronectin activated both monocytes and macrophages via integrin receptor ‘outside in’ signalling, triggering an ERK:AP-1 cascade and expression of pro-inflammatory cytokines MCP-1 and TNFα to drive additional recruitment of circulating leukocytes. IsoDGR-modified fibronectin also induced endothelial cell expression of integrin β1 to further enhance cellular adhesion and matrix deposition. Analysis of murine aortic tissues confirmed accumulation of isoDGR-modified proteins co-localised with CD68+ macrophages in vivo.Conclusions Age-damaged fibronectin features isoDGR motifs that increase binding to integrins on the surface of monocytes, macrophages, and endothelial cells. Subsequent activation of ‘outside-in’ signalling elicits a range of potent cytokines and chemokines that drive additional leukocyte recruitment to the developing atherosclerotic matrix.HighlightsIsoDGR-modified plasma proteins are associated with CAD.IsoDGR binding to integrin receptors on monocytes, macrophage, and endothelial cells promotes ‘outside-in’ signalling, monocyte infiltration, and endothelial binding.IsoDGR-modified fibronectin may initiate vascular inflammation in atherosclerotic CVD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was in part supported by grants from the National Medical Research Council of Singapore (NMRC-OF-IRG-0003-2016) and Ministry of Education of Singapore (MOE2018-T1-001-078).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards of NTU (IRB-2017-01-013), NUHS (IRB-NUH-2009-0073) and TTSH (TTSH-2013-00930). Experimental procedures complied with the tenets of the Declaration of Helsinki. Informed written consent was obtained from each subject prior to the inclusion in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and results are provided as supplementary data